Liver cirrhosis
Drug research and approvals for liver cirrhosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 351 studies of liver cirrhosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 351
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisNCT07920744 · Not reported · Fifth Affiliated Hospital, Sun Yat-Sen University · starts Oct 28, 2026
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNCT07923318 · Not applicable · Chonnam National University Hospital · starts Oct 4, 2026
- Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal…NCT07918378 · Not reported · University Medical Center Ho Chi Minh City (UMC) · starts Oct 1, 2026
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDNCT07877272 · Not reported · University Hospital Muenster · starts Oct 5, 2026
- EUS-Guided Coil and Glue vs Glue Injection for Bleeding Gastric Varices in CirrhosisNCT07855913 · Not applicable · Medanta, The Medicity, India · starts Sep 1, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic…NCT07847710 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Sep 30, 2026
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNCT07841977 · Phase 2 · Gilead Sciences · starts Oct 1, 2026
- Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of LiverNCT07816094 · Phase 4 · Bangladesh Medical University · starts Jan 1, 2026
Approved 5
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- SpironolactoneMineralocorticoid receptor antagonist
- TriamtereneAmiloride-sensitive sodium channel, ENaC blocker
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
Phase 3 12 of 27
- SatavaptanVasopressin V2 receptor antagonist
- RifaximinBacterial DNA-directed RNA polymerase inhibitor
- TolvaptanVasopressin V2 receptor antagonist
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- SimvastatinHMG-CoA reductase inhibitor
- Albumin humanBilirubin sequestering agent
- Calcium carbonate
- LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- NorfloxacinTopoisomerase IV inhibitor
- PropranololBeta-1 adrenergic receptor antagonist
- RivaroxabanCoagulation factor X inhibitor
Phase 2 12 of 26
- ApixabanCoagulation factor X inhibitor
- AllopurinolXanthine dehydrogenase inhibitor
- SomatropinGrowth hormone receptor agonist
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- EmricasanCaspase inhibitor
- Epigalocatechin gallate
- BosentanEndothelin receptor, ET-A/ET-B antagonist
- ImiquimodToll-like receptor 7 agonist
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- EdoxabanCoagulation factor X inhibitor
- Enoxaparin sodiumAntithrombin-III activator
- ConivaptanVasopressin V2 receptor antagonist
Phase 1 or earlier 12 of 18
- TilarginineNitric oxide synthase inhibitor
- EltrombopagThrombopoietin receptor agonist
- SildenafilPhosphodiesterase 5A inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- UrsodiolBile acid receptor FXR agonist
- ColchicineTubulin inhibitor
- SaroglitazarPeroxisome proliferator-activated receptor alpha agonist
- Interferon
- Ornithine
- Bifendate
- PegbelferminFGF1/KLB agonist
- Lixudebart
How its trials ended
1,546 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 269 whose ending is known, 36% met their primary endpoint, 7% missed it and 56% stopped early.
- Completed, result not reported51133%
- Status unknown40226%
- Ongoing36424%
- Met its primary endpoint986%
- Stopped: other or unclear835%
- Stopped: enrollment or feasibility352%
- Missed its primary endpoint201%
- Stopped: sponsor or business decision131%
- Stopped: lack of efficacy111%
- Stopped: funding5<1%
- Stopped: safety4<1%
| Oct 22, 2026 | LynavoyLinerixibat · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Sep 19, 2024 | IqirvoElafibranor · orphan | Ipsen Pharma | EMA ↗ |
| not available | Lyvdelzi (previously Seladelpar Gilead)Seladelpar lysine dihydrate · orphan | Gilead Sciences Ireland Unlimited Company | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA